Search

Roche announced that Elecsys pTau217, the first blood test specifically designed to signal and rule out Alzheimer's disease, has received CE Mark approval for use in Europe, promising faster diagnoses for millions of patients by detecting pTau217 protein levels, thereby indicating the likelihood of Alzheimer's while potentially reducing the need for more invasive testing. #AlzheimersDisease #Diagnostics #HealthcareInnovation #EU #CH

Roche has received clearance for Elecsys pTau217, the first blood test designed to diagnose and rule out Alzheimer's disease in Europe, which promises faster diagnoses for millions of patients by detecting levels of a protein linked to the disease. #AlzheimersDisease #BloodTest #HealthcareInnovation #EU #CH #US